Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
For the millions of people living with depression that has not responded to standard treatments, ketamine therapy represents a potentially transformative option. Unlike conventional antidepressants that target serotonin or norepinephrine and can take weeks to show effects, ketamine works through an entirely different mechanism and may produce noticeable improvements much more rapidly. This guide covers the clinical evidence, how ketamine treats depression differently, the various treatment options available, and what you should know before considering this therapy.
Treatment-resistant depression (TRD) is generally defined as depression that has not improved after trying at least two different antidepressant medications at adequate doses for sufficient durations. By some estimates, up to one-third of people with major depressive disorder may fall into this category, making TRD a significant clinical challenge.
For patients with TRD, the journey through multiple failed medications can be deeply demoralizing. Each trial typically requires four to eight weeks to evaluate, meaning patients may spend months or years cycling through treatments that do not work. This is compounded by the side effects of antidepressants, which can include weight gain, sexual dysfunction, emotional blunting, and other challenging effects.
If you have experienced this pattern, you are not alone. Our article on what to do when antidepressants do not work outlines the alternatives that may be available. Understanding TRD is important because it helps frame why novel treatments like ketamine are being explored, and why they may be most appropriate for patients who have already tried conventional options. For more information, visit our treatment-resistant depression page.
The fundamental difference between ketamine and traditional antidepressants lies in their mechanisms of action. SSRIs, SNRIs, and other first-line medications primarily modulate serotonin and norepinephrine levels. Ketamine, by contrast, targets the glutamate system, the brain's primary excitatory neurotransmitter system. For a thorough explanation of this mechanism, read our post on ketamine's rapid antidepressant mechanism through NMDA and glutamate.
Ketamine blocks NMDA receptors, which paradoxically triggers a surge of glutamate release. This glutamate surge activates AMPA receptors, initiating a signaling cascade that increases the production of brain-derived neurotrophic factor (BDNF) and stimulates the mTOR pathway. The result is rapid synaptogenesis, the formation of new synaptic connections, particularly in the prefrontal cortex, a brain region often impaired in depression. Our article on ketamine, BDNF, and neuroplasticity explores this science in greater depth.
Perhaps the most remarkable aspect of ketamine for depression is the speed at which it can work. While SSRIs require gradual changes in synaptic serotonin levels over weeks, ketamine's glutamate-mediated effects on neural plasticity can occur within hours. This rapid onset is particularly significant for patients experiencing suicidal ideation, where the wait for conventional treatments to take effect can be dangerous. Our post on ketamine's rapid reduction of suicidal ideation reviews the evidence.
Some researchers and clinicians believe that the subjective psychological experience during a ketamine session may also contribute to its antidepressant effects. The mild dissociative state may allow patients to gain a different perspective on entrenched thought patterns and emotional responses. This is why many providers emphasize the value of integration therapy and journaling as part of a comprehensive treatment approach. For a broader look at how ketamine works, see our overview article: How Does Ketamine Work?
The body of evidence supporting ketamine for depression has grown substantially over the past two decades. Since the pivotal 2000 study by Berman and colleagues, dozens of randomized controlled trials, meta-analyses, and real-world studies have been published.
One of the most rigorous studies compared ketamine to an active placebo (midazolam) in patients with treatment-resistant depression. Our review of the ketamine vs. midazolam depression trial provides a detailed analysis. The study found that ketamine produced significantly greater improvement in depressive symptoms within 24 hours compared to midazolam, with the difference maintained over the study period.
Meta-analyses pooling data from multiple trials have consistently supported ketamine's rapid antidepressant effects. Response rates in treatment-resistant populations have generally ranged from approximately 50 to 70 percent, though it is important to note that not all patients respond. For a curated list of foundational research, see our post on 6 research papers to read about oral ketamine for depression.
Beyond clinical trials, real-world data from clinical practice has also been encouraging. Studies examining sublingual ketamine outcomes in real-world settings have reported meaningful improvements in depression scores. Research on ketamine-assisted psychotherapy outcomes suggests that combining ketamine with therapeutic support may enhance and extend benefits.
Researchers are actively working to identify who is most likely to benefit from ketamine therapy. Our article on predictors of ketamine treatment response and biomarkers reviews the current understanding. Factors being studied include genetic markers, neuroimaging patterns, and clinical characteristics such as severity of depression and history of previous treatment response.
A board-certified Isha Health physician can evaluate whether ketamine therapy may be appropriate for you.
Book a ConsultationUnderstanding how ketamine compares to other available treatments can help you and your provider determine the most appropriate path. We have developed detailed comparison guides for each of these options:
While SSRIs and SNRIs remain first-line treatments, ketamine offers a fundamentally different approach for patients who have not responded. Key differences include speed of onset (hours vs. weeks), mechanism of action (glutamate vs. serotonin), and route of administration. Read our full comparison: Ketamine vs. Antidepressants. You may also find our post on how ketamine differs from traditional antidepressants helpful.
Transcranial magnetic stimulation (TMS) is another option for treatment-resistant depression. TMS is FDA-cleared for depression and uses magnetic pulses to stimulate brain regions. Unlike ketamine, TMS requires daily clinic visits over four to six weeks. See our detailed comparison: Ketamine vs. TMS.
Electroconvulsive therapy (ECT) has long been considered the gold standard for severe, treatment-resistant depression. While ECT has strong efficacy data, it requires general anesthesia, involves a risk of memory side effects, and carries significant stigma. Ketamine may offer a less invasive alternative for some patients. Compare the two approaches: Ketamine vs. ECT.
Psychotherapy remains a cornerstone of depression treatment. Rather than viewing ketamine as a replacement for therapy, many clinicians see them as complementary. Ketamine may help open a window of neuroplasticity during which therapy can be more effective. See Ketamine vs. Therapy and our article on ketamine-assisted psychotherapy.
Interest in psychedelic-assisted therapy has surged in recent years. Psilocybin, MDMA, and other substances are being studied for depression and PTSD. Ketamine is currently the only psychedelic-adjacent substance that can be legally prescribed by physicians in all 50 states for mental health use. For comparisons, see Ketamine vs. Psilocybin and our post on psilocybin vs. ketamine for depression.
One of the most common questions patients ask is whether they should pursue at-home oral ketamine or in-clinic IV infusions. Both approaches have demonstrated therapeutic potential, and the right choice depends on your individual circumstances, preferences, and clinical needs.
For a detailed side-by-side comparison, read our guides on oral ketamine vs. IV infusion and at-home ketamine vs. clinic-based treatment.
| Factor | At-Home Oral Ketamine | IV Ketamine in Clinic |
|---|---|---|
| Convenience | Treatment from home; no travel required | Requires travel to a clinic; appointments may be limited |
| Cost | Generally more affordable ($350/appt + medication) | Typically $400-$800+ per infusion session |
| Bioavailability | Lower (~25-35% sublingual); doses adjusted accordingly | Near 100%; most precise dosing |
| Clinical evidence | Growing body of real-world data and clinical studies | Most extensively studied route in clinical trials |
| Medical oversight | Telehealth physician supervision; support person present | In-person medical staff during infusion |
At Isha Health, we provide at-home oral ketamine therapy with comprehensive physician oversight. Our approach includes an initial 60-minute evaluation, personalized dosing protocols, medication delivered to your home, and ongoing follow-up appointments. Learn more about at-home ketamine therapy for depression.
Understanding realistic expectations is important for anyone considering ketamine therapy. While the research is encouraging, individual responses vary significantly.
Some patients report mood improvements within hours to days of their first session. During the initial phase, sessions are typically more frequent, often two to three per week for IV infusions or weekly for oral ketamine. Not all patients respond during this initial phase, and some may require dose adjustments.
As treatment continues, the goal is to build on initial improvements and establish more sustained relief. This is a critical period for combining ketamine with integration practices such as therapy, journaling, mindfulness, and lifestyle changes. Treatment frequency may begin to decrease.
For many patients, ongoing maintenance sessions at reduced frequency help sustain the benefits of treatment. The optimal maintenance schedule varies by individual. Our article on how long ketamine's antidepressant effects last explores what the research shows about durability of response.
It is also important to address the question of how long you need to be on ketamine. The answer depends on individual response, goals, and whether other therapeutic supports are in place. Some patients eventually taper off ketamine after establishing stability, while others benefit from ongoing low-frequency maintenance.
Ketamine therapy may be worth exploring if you meet certain criteria. Generally, candidates for ketamine treatment:
Take our Am I a Candidate? assessment to get a preliminary sense of whether ketamine therapy might be appropriate for your situation. This is not a substitute for a clinical evaluation, but it can help you prepare for a conversation with a provider.
If you decide to move forward, understanding how to choose a ketamine therapy provider is an important next step. Not all providers offer the same level of care, and the quality of medical oversight and integration support can significantly influence your outcomes.
Schedule a consultation with a board-certified Isha Health physician to discuss whether ketamine therapy may help your depression.
Schedule Your ConsultationClinical trials have reported response rates of approximately 50 to 70 percent in patients with treatment-resistant depression, though individual results vary. Some patients report improvement within hours to days. See our article on ketamine clinical trial data for details.
Effects from a single treatment may last from several days to about two weeks. Repeated treatments and maintenance sessions can sustain improvement. Read more about ketamine's antidepressant durability.
Ketamine is FDA-approved as an anesthetic, not specifically for depression. It is prescribed off-label for depressive disorders. Esketamine (Spravato) is the only ketamine-derived product FDA-approved for treatment-resistant depression. Learn about the FDA approval process for ketamine.
IV ketamine is administered in a clinical setting with near-100% bioavailability. Oral ketamine can be taken at home with lower bioavailability but greater convenience and affordability. Both have shown therapeutic potential. See our detailed comparison.
Many patients begin ketamine therapy while still taking their existing antidepressants. Your prescribing physician will review your current medications to ensure safety. Some patients may eventually taper their antidepressants under medical guidance.
Adults with moderate to severe depression who have not responded to at least two conventional treatments may be candidates. A thorough evaluation is required. Visit our Am I a Candidate? page for an initial assessment.
Medical disclaimer: This guide is for informational purposes only and does not constitute medical advice. Ketamine is FDA-approved as an anesthetic; its use for depression is off-label. Esketamine (Spravato) is FDA-approved for treatment-resistant depression. Always consult with a qualified healthcare provider before starting any new treatment. Last updated: April 2026.
